We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Heart Failure Patients’ Blood Glucose Levels Predict Mortality Risk

By LabMedica International staff writers
Posted on 18 Jan 2015
The prognostic implications of blood glucose on a wide range of outcomes including early mortality, hospitalizations, and incident diabetes diagnoses have not been fully elucidated in acute heart failure syndromes (AHFS).

People who arrive at hospital emergency departments with acute heart failure should have their blood sugar levels checked on arrival as this simple and inexpensive measure could identify patients at high risk of early death, further hospitalizations, or the development of more health problems, such as diabetes.

Clinical scientists at the Institute for Clinical Evaluative Sciences (Toronto, ON, Canada) performed a competing risk analysis for 30-day mortality, new diabetes diagnoses, and hospitalization outcomes in a population-based cohort of 16,524 AHFS patients presenting to the emergency department (ED) in Ontario (Canada) between 2004 and 2007. More...
Presentation blood glucose concentrations were categorized as follows: 3.9–6.1 (reference), >6.1–7.8, >7.8–9.4, >9.4–11.1, and >11.1 mmol/L.

The investigators found that patients without preexisting diabetes had a risk of death within 30 days from any cause that was 26% higher than the reference group if their blood glucose levels were between 6.1–7.8 mmol/L, rising to 50% higher if their levels exceeded 11.1 mmol/L. Their risk of death from cardiovascular causes was 28% higher for levels between 6.1–7.8 mmol/L, rising to 64% higher for levels between 9.4–11.1 mmol/L. As their blood glucose levels rose, so did their risk of subsequently developing diabetes; for levels between 6.1–7.8 mmol/L, their risk of diabetes was 61% higher, and this rose by 14% for every 1 mmol/L increase in blood glucose. If their levels exceeded 11.1 mmol/L, their risk of diabetes was 261% higher. Among all patients, with and without preexisting diabetes, blood sugar levels above 9.4 mmol/L increased the risks of hospitalization by 9%–15% for heart failure or cardiovascular causes.

Douglas S. Lee, MD, PhD, an Associate Professor of Medicine, and lead author of the study, said, “Our findings suggest that the measurement of blood sugar levels in all patients arriving at emergency departments with acute heart failure could provide doctors with useful prognostic information and could help to improve outcomes in these patients. It is a rapid, readily available and inexpensive test that could be used to enable doctors to quickly assess a patient’s risk for a wide range of possible outcomes and to suggest appropriate screening strategies that should be put in place.” The study was published on January 7, 2015, in the European Heart Journal.

Related Links:

Institute for Clinical Evaluative Sciences 



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Urine Test Strips
LabStrip U12 mALB/CREA
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.